Peptides Codex
ENFR
← Home
Research / clinical peptide

Sermorelin

Sermorelin is a synthetic 29-amino-acid analog of growth hormone–releasing hormone (GHRH 1-29). It is widely searched in GH-axis education and specialty practice discussions.

By The Peptides Codex Editorial TeamReviewed July 10, 2026
Length
29 aa
Class
Research / clinical peptide
Function
GHRH fragment stimulating pituitary GH release
Context
Historically used clinically in some settings; research and specialty use varies by country

Shorter GHRH analog — bridge between endogenous GHRH and longer analogs like CJC-1295.

Also known as: GHRH 1-29 · GRF 1-29

Part of the Growth hormone & IGF peptides cluster

Overview

Sermorelin is a synthetic 29-amino-acid analog of growth hormone–releasing hormone (GHRH 1-29). It is widely searched in GH-axis education and specialty practice discussions.

Source & context

Biological / chemical source: Synthetic GHRH (1-29) amide

Primary research or clinical context: Historically used clinically in some settings; research and specialty use varies by country

Relationship to CJC-1295

Sermorelin represents a relatively direct GHRH fragment approach, while CJC-1295 variants add half-life extension strategies. Comparing them is a common educational query.

FAQ about Sermorelin

What is Sermorelin?+

Sermorelin is a synthetic 29-amino-acid analog of growth hormone–releasing hormone (GHRH 1-29). It is widely searched in GH-axis education and specialty practice discussions.

Is Sermorelin an approved medicine?+

Sermorelin is discussed here as a research / educational topic. Historically used clinically in some settings; research and specialty use varies by country. This is not medical advice.

What is the typical length of Sermorelin?+

Sermorelin is commonly described as approximately 29 amino acids (Research / clinical peptide).

Related peptides

GLP-1
Incretin
GLP-1 (glucagon-like peptide-1) is an incretin hormone that stimulates insulin secretion and influences appetite. Engineered analogs dominate modern metabolic medicine research.
Semaglutide
Incretin analog
Semaglutide is a modified GLP-1 receptor agonist peptide designed for extended half-life. It is an approved prescription medicine in many jurisdictions and a major case study in peptide engineering.
CJC-1295
Research peptide
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) studied for effects on the GH/IGF-1 axis. Variants with and without DAC (Drug Affinity Complex) appear in research discussions.
Ipamorelin
Research peptide
Ipamorelin is a selective growth hormone secretagogue receptor agonist peptide studied for GH release with a relatively focused receptor profile compared with earlier GHRPs.

References & further reading

  1. 1.Wikipedia — Sermorelin
  2. 2.PubChem — compound summary for Sermorelin (CID 16132413)
  3. 3.Prakash et al. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs
  4. 4.Chen et al. (1993). A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta Paediatr Suppl
  5. 5.Thorner et al. (1996). Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab
  6. 6.Kirk et al. (1994). Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. Clin Endocrinol (Oxf)
  7. 7.Neyzi et al. (1993). Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta Paediatr Suppl
  8. 8.Arrigo et al. (1992). Diagnostic value of growth hormone-releasing hormone test in children and adolescents with idiopathic growth hormone deficiency. Eur J Pediatr
  9. 9.Ranke et al. (1986). Testing with growth hormone-releasing factor (GRF(1-29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency. Eur J Pediatr
  10. 10.Albini et al. (1988). Diagnostic value of the growth hormone-releasing factor stimulation test. Clin Pharmacol Ther
  11. 11.Losa et al. (1984). Stimulation of growth hormone secretion with human growth hormone releasing factors (GRF1-44, GRF1-40, GRF1-29) in normal subjects. Klin Wochenschr
  12. 12.Vittone et al. (1997). Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism
  13. 13.Khorram et al. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab
  14. 14.Baker et al. (2012). Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol
  15. 15.Friedman et al. (2013). Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol
  16. 16.Walker (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clin Interv Aging
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — Sermorelin educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.